INTRODUCTION
Peripheral Tcell lymphomas (PTCLs) are aggressive neoplasms that account for less than 15% of all nonHodgkin lymphomas (NHLs) in adults. PTCL not otherwise specified (PTCLNOS) is a heterogeneous group comprised of predominantly nodal Tcell lymphomas that do not satisfy the criteria for the other sub types of PTCLs [1] . Most cases of PTCLNOS are often associated with generalized lymphadenopathy with or without extranodal disease, which involves the gastrointestinal tract, liver, spleen, skin, oropharynx, nasopharynx, sinuses, nasal cavity, tonsils, and bone marrow [2] . Most patients with hepatic lymphoma have been reported to have variable imaging findings, ranging from single or multiple small nodules to diffuse infiltration [3, 4] . Here, we report an atypical case of primary hepatic PTCLNOS that exhibited a solitary hepatic mass mimicking hepatocellular carcinoma (HCC).
CASE REPORT
A 50yearold male patient presented with a month history of general fatigue and weakness. He did not have fever, weight loss, or night sweating. Physical examination of the patient was unremarkable with no peripheral lymphadenopathy. The pa tient had no notable past medical history. Laboratory studies con ducted on admission showed the following results: WBC, 13.12 × 10 Peripheral T-cell lymphomas (PTCLs) are aggressive neoplasms which may involve the liver. The imaging manifestations of hepatic lymphoma are highly variable and show overlapping appearances of numerous other hepatic diseases. As the man agement and prognosis of lymphoma differ markedly from those of other malignant diseases, prompt diagnosis and early effective treatment are very important. Here, we report an atypical case of primary PTCL not otherwise specified involving the liver that exhibited a solitary hepatic mass mimicking hepatocellular carcinoma (HCC) on CT. Liver biopsy is not commonly recommended in highly suspicious cases of HCC. However, in a patient without risk factors for HCC, consi deration of other diagnostic possibilities is required and needle biopsy may be a more rational choice. An imaging approach, based on a careful review of clinical and laboratory findings is essential to prevent false-positive diagnosis of HCC and subsequent invasive treatment. hr). All values were higher than the normal range. Values for hemoglobin, total bilirubin, αFP, albumin, creatinine, and PT were within normal limits. CEA was slightly elevated at 5.7 ng/ mL (normal range, ≤5.0 ng/mL), and other tumor markers, such as αFP and CA 199, were within normal ranges. Serologic tests including human immunodeficiency virus, syphilis antibody, and hepatitis C and B viruses were negative.
Diagnostic imaging was performed using abdominal CT (Brilliance CT 64 Channel, Philips Medical, Eindhoven, the Netherlands). Prior to contrast material injection, abdominal CT revealed a well circumscribed, round, homogeneous, and low density mass that measured 65 mm × 60 mm in the largest diameter located in segment V of the liver. Dynamic contrast enhanced CT revealed a welldefined mass with moderate enhancement in the arterial phase and washout of contrast media in the portal venous phase and delayed phase. Peripheral rimenhancement was observed and was more obvious in the delayed phase (Fig. 1) . The enhancement patterns of hepatic mass appeared suspicious for hypervascular hepatic tumor, such as HCC, despite the patient having no risk factors for HCC. Contrastenhanced abdomen CT also revealed multiple enlarged mesenteric and retroperitoneal lymph nodes with homogeneous enhancement, and this finding suggested a malig nant lymphoproliferative disorder such as lymphoma (Fig.   1E ). Most cases of hepatic lymphoma have been reported to have variable imaging findings, ranging from single or multiple small nodules to diffuse infiltration. However, these patterns did not correlate with our imaging findings of the hepatic mass.
As the radiologic features of the lesion were more indicative of HCC, right hepatectomy was undertaken. Grossly, the sur gical specimen exhibited a greywhite mass, measuring 70 mm × 50 mm × 50 mm in segment V of the liver. The mass was firm and well demarcated from the surrounding tissue ( Fig.  2A) . The patient had multiple intraabdominal enlarged lymph nodes, but no tumor cells were found on frozen biopsy. Micro scopic examination of the mass revealed a diffuse infiltration of mediumsized monotonous lymphoid cells surrounded by peritumoral fibrosis and ductular reaction (Fig. 2B) . The lym phoid cells demonstrated positive reaction to CD3, CD4, CD5, and CD8, and negative reaction to CD20 and cyclin D1 in immunohistochemical staining. Additionally, tumor cells stained positive for CD31, which is known to be an endothelial marker of microvessels (Fig. 2C) . The molecular pathological evalua tion for the EpsteinBarr virus showed a negative result. Based on the histological and immunohistochemical findings, the diagnosis of hepatic mass was confirmed as primary hepatic PTCLNOS.
The patient then underwent treatment with a total of 6 cycles of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone). However, after 7 months of operation, local recurrence was suspected on followup CT and positron emis sion tomography CT. In addition, increased size of several enlarged lymph nodes was observed in the abdomen. Although recurrence was observed, the patient withdrew from further treat ment because of financial difficulties and underwent conservative management.
DISCUSSION
PTCLs are highly aggressive diseases and constitute 5%-15% of all NHL. PTCLNOS is a heterogeneous group comprised of predominantly nodal Tcell lymphomas that do not satisfy the criteria for other subtypes of PTCLs [1] . The median age at diagnosis is 60 years, and the disease is relatively more common in men (approximately 2:1). Approximately 35% of patients of PTCLs have systemic B symptoms (fever, night sweats, weight loss). Half of patients are associated with an elevated LDH level and 14% of patients have hypergammaglobulinemia [2] . In the present case, the patient did not have any B symptoms, but the LDH level was elevated at 1,430 IU/L. PTCLNOS often affects the systemic lymph nodes and extra nodal sites, which involve the gastrointestinal tract, liver, spleen, skin, oropharynx, nasopharynx, sinuses, nasal cavity, tonsils, and bone marrow [2] . According to the criteria by Caccamo et al. [3] , primary hepatic lymphoma (PHL) is defined as a lymphoma with involvement of only the liver at presentation. Six months after the diagnosis, other tissues can be involved, including the spleen, lymph nodes, peripheral blood, bone marrow, or other tissues. PHL is very rare; it constitutes 0.4% of extranodal NHLs, and only 0.016% of all cases of NHLs. Imaging findings of hepatic lymphoma vary. PHL typically appears in one large nodule with clear boundaries, whereas secondary hepatic lymphoma can vary in appearance, from one or multiple nodules to diffuse infiltration [4] . The lesion usually shows a homogeneously hypodense appearance on noncontrastenhanced CT imaging. Upon administration of an intravenous contrast agent, lymphomatous nodules commonly enhance to a lesser degree than the hepatic parenchyma on arterial, portal venous, and delayed phase images, indicating the hypovascular nature of lymphoma. The lesions may exhibit hemorrhage, necrosis, or a rimenhancement pattern [46] . In the present case, dynamic contrastenhanced CT revealed a welldefined mass with moderate enhancement in the arterial phase, and washout of contrast media in the portal venous phase and delayed phase, accounting for the characteristic enhancement pattern of HCC. CastañedaZuñiga and Amplatz [7] reported a hepatic lymphoma with the presence of neovas cularity, stretching, narrowing of arteries, and dense staining during the parenchymal phase of hepatic angiography. This hyper vascular angiographic appearance, which is highly un usual for hepatic lymphoma, might be concordant with the CT finding of moderate enhancement on the arterial phase in our case. In the present case, tumor cells stained positive for CD31, which is known to be endothelial marker of microvessels [8] . We hypothesized that hyperproliferation of microvessels might influence relative hypervascularity of this tumor and show moderate enhancement on the arterial phase CT imaging. How ever, to the best of our knowledge, the mechanism of the unusual hypervascular pattern of hepatic lymphoma has not yet been discussed. The other pattern of peripheral rimenhancement of the hepatic lymphoma reported in previous studies [5, 6] was consi stent with our finding. The presence of a fibrous tumor capsule is the characteristic feature of HCC and is found in 24%-90% of Asian and 12%-42% of nonAsian patients with HCC [9] . Mean thickness of tumor capsule was 0.3-1.4 mm (0.87 ± 0.59 mm) in pathological measurement, and thin rim enhancement (less than 2 mm) was shown in 98% of them on imaging finding [10] . Nevertheless, our case showed the peripheral enhancement measuring approximately 5.5 mm, which was thicker than that seen in typical HCC. We hypothesized that the rimenhance ment pattern of the hepatic lymphoma does not indicate a true tumor capsule, but rather peritumoral fibrosis and ductular reaction, likely caused by effect of the mass.
Although recent studies have shown improved detection of hepatic lesions, there exists a risk of misdiagnosis of HCC as incidental benign lesion or nonhepatocellular malignancy. Liver biopsy is not commonly recommended in highly suspicious cases of HCC, in clinical routine processes. However, when radio logical findings show a typical appearance of HCC in a patient without risk factors for HCC, consideration of the other diag nostic possibilities is required. In this case, a needle biopsy may be a more rational choice.
Treatment for hepatic lymphoma usually consists of chemo therapy dictated by the histologic subtype. Therefore, suggesting a diagnosis of hepatic lymphoma rather than HCC, metastasis, or infection facilitates appropriate management because surgery or liverdirected therapy for HCC and metastasis or antibiotic administration and drainage for infection may be precluded.
In conclusion, we presented an atypical case of primary hepatic PTCLNOS with a solitary mass mimicking HCC. We did not perform liver biopsy because we believed the hepatic mass was HCC. However, consideration of the other differential diagnoses is required, particularly when serum AFP is normal and a patient has no risk factors for HCC, and needle biopsy should be performed before operation. An imaging approach, based on a careful review of clinical and laboratory findings is essen tial to prevent falsepositive diagnosis of HCC and subse quent invasive treatment.
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